You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The offer of $402 per share was made in connection with Abbott's acquisition of Alere, which was completed on Tuesday.
The firm intends to use some of the proceeds for ongoing development of its Cchek series of noninvasive blood tests for the early detection of solid tumor-based cancers.
The company will use the net proceeds to finance its current operations and expand its US commercialization capacities for its lead product, Epi proColon.
The offering of nearly 4.4 million shares was priced at $4 per share, and the underwriters exercised their option to purchase an additional 656,250 shares of T2’s common stock
The cancer diagnostics company went public today on the Nasdaq with an initial public offering of 2.4 million shares, priced at $9.50 per share.
The Lexington, Massachusetts-based firm plans to offer about 4.4 million shares of its common stock at a price of $4 per share.
The cell-based cancer diagnostics firm said in an SEC filing that it plans to offer 2 million shares of its common stock at between $8 and $10 per share.
The company said it will use the proceeds from the offering for working capital and general corporate purposes, among other things.
The shelf registration follows a recent $56.5 million financing and comes amid an expansion of the firm's commercial operations.
Its technology called CELx uses a patient's tumor cells to identify abnormal cellular activity driving their cancer and the most appropriate therapy.